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Summary
Several pathogenetic factors seem to contribute to the
development of Alzheimer’s disease (AD). Some data
point to a role for traumatic brain injury (TBI), but this
suggestion is not universally supported. Mayeux et al.
have shown that TBI increases the risk of AD, but only
through a synergistic relationship with apolipoprotein
epsilon (Apo E) 4. We present the results of a cross-sec-
tional and longitudinal study of the relationship between
these factors, conducted in northern and southern Italy.
We studied 337 consecutive patients with probable AD
and 63 subjects with mild cognitive impairment (MCI).
Information concerning head injuries was collected by
interview of informants and review of medical records.
Twenty-one patients with AD and 9 with MCI were found
to have a history of TBI with loss of consciousness. AD
and MCI patients with a history of TBI, compared with
control groups matched for age, sex, education and de-
gree of mental impairment, showed more marked de-
pressive and behavioural disturbances (Global Deterio-
ration Scale and Neuropsychiatric Inventory, p<0.05).
Six- and 12-month follow up of both groups did not
show significant differences in the rate of progression
of cognitive changes.
A high frequency of Apo E 4 was detected in the pa-
tients with TBI and cognitive impairment (40.5% in the
AD and 11% in the MCI subgroups). The distribution of
the epsilon 4 allele in our control group was 4%, com-
parable to that found in the Italian population. Distribu-
tion of the above parameters was similar in patients
from northern and southern Italy.
The higher frequency of TBI and Apo E 4 genotype
among AD and MCI patients confirms the synergistic
interaction of environmental and genetic factors in the
development of dementia. Our data do not suggest that
the presence of these two factors influences the clini-
cal presentation or the course of the disease. 
KEY WORDS: Alzheimer’s disease, apolipoproteins, mild cognitive
impairment, traumatic brain injury.
Introduction
Studies of risk factors in Alzheimer’s disease (AD) sug-
gest the interaction of multiple pathogenetic factors,
leading to the concept of “convergence syndrome” as
proposed by Blass et al. (1). Traumatic brain injury (TBI)
is one of the factors thought to be related to the patho-
genesis of AD, its role first being suggested by epidemi-
ological studies (2). This suggestion was later support-
ed by the description of AD-like neuropathological
changes in dementia pugilistica (3). Other epidemiolog-
ical studies, however, have given rather ambiguous
(4,5) or even conflicting findings (6-9).
Mayeux and collaborators were the first to show that
TBIs may increase the risk of AD through a synergistic
relationship with apolipoprotein epsilon (Apo E) 4 (10,
11). Data from the MIRAGE (Multi-Institutional Research
in Alzheimer Genetic Epidemiology) project (12), as well
as a recent review (13), have shown a complex relation
between these factors. An interaction between Apo E
and TBI is also suggested by some animal studies (14,15).
We present the results of a cross-sectional study of the
relationship between TBI and Apo E conducted in north-
ern and southern Italy. In addition to investigating geno-
typic factors and history of TBI in AD, we enroled a
group of subjects with mild cognitive impairment (MCI),
and a control group. We hypothesized that we would
find an association between Apo E 4 and TBI not only in
AD, but also in MCI patients. We further hypothesized
that a history of TBI would be a predictor of a worse clin-
ical outcome, including conversion from MCI to AD.
Materials and methods
The study included 337 consecutive patients with diag-
nosis of probable AD and 63 subjects with MCI. The pa-
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tients with probable AD were selected in accordance
with the NINCDS-ADRDA criteria (16); those with MCI
were selected using the criteria of Petersen et al. (17). 
The quantification of cognitive and functional status was
obtained using the following tests and scales: 
Mini Mental State Examination (MMSE, range 0 to 30),
and the Clinical Dementia Rating Scale (CDR), range 0
to 5, to assess global cognitive impairment (18,19);
Attention matrices: number cancellation task to evaluate
selective attention (range 0-60)(20);
Corsi’s span: short-term visuo-spatial memory test
(range 0-10) in which the examiner shows a progres-
sively growing sequence of visual stimuli (cubes
arranged on a board), and the subjects try to repeat the
sequence (20);
Digit span: short-term verbal memory test (range 0-10)
in which the subjects listen to and try to repeat correctly
a growing sequence of digits (20);
Mental Deterioration Battery (MDB) (21), comprised of
eight tests, four that express the processing of verbal
material and the other four the processing of visuospa-
tial material. The verbal tests are: immediate and de-
layed recall of Rey’s 15 words (range 0-75, 0-15 respec-
tively), word fluency (FAS), phrase construction (range
0-25). The visuospatial tests are: Raven’s 47 progres-
sive coloured matrices (range 0-36), immediate visual
memory (range 0-22), and copying of drawings freehand
(range 0-12) and with landmarks (range 0-70).
Affective symptoms were assessed using the Geriatric
Depression Scale (GDS) (22). 
The Neuropsychiatric Inventory (NPI) and its subscales
were used to evaluate behavioural symptoms and care-
giver distress (23).
The Instrumental Activities of Daily Living (IADL) (24)
and Activities of Daily Living (ADL) scales (25) were al-
so applied to evaluate functional status.
Information concerning head injuries was collected by
interview of multiple informants and review of medical
records. The definition of traumatic events followed the
guidelines proposed by Bevilacqua et al. (26). Accord-
ingly, events were coded as follows:
– asymptomatic: no loss of consciousness, no amnesia,
normal neurological examination;
– mild: no loss of consciousness, normal neurological
examination, but vomiting and headache;
– moderate: post-traumatic amnesia of less than an
hour, short loss of consciousness with complete recov-
ery within an hour, normal neurological examination, but
persisting headache and/or vomiting and/or post-trau-
matic confusion;
– moderate to severe: loss of consciousness or confu-
sion, lasting up to 24 hours, post-traumatic amnesia for
one to two hours, repeated and persistent headache
and/or vomiting, possible signs or symptoms suggesting
a focal neurological deficit;
– severe: loss of consciousness or confusion lasting over
24 hours, post-traumatic amnesia for one to seven days;
there may or may not be presence of neurological signs.
The determination of the Apo E genotype was per-
formed at the CNR Institute of Neurological Sciences,
Cosenza, Italy.
Genomic DNA was extracted from leukocytes harvest-
ed from whole blood using standard methods and the
Apo E genotyping was performed using the following
oligonucleotide primers (reverse 5’-ACAGAATTCGC-
CCCGGCCTGGTACACTGCCA-3’) and (forward 
5’-TAAGCTTGGCACGGCTGTCCAAGGA-3’). Each re-
action mixture was heated at 94°C for 5 min, and sub-
mitted to 35 cycles as follows: denaturation at 94°C for
30 s, annealing at 65°C for 30 s, followed by extension
at 70°C for 1 min and 30s, then a final extension at 70°C
for 10 min. After polymerase chain reaction amplifica-
tion, 10 units of CfoI (Boehringer, Mannheim) were
added directly to each reaction mixture for digestion of
Apo E sequences and left for at least 3 h at 37°C. Each
digested unit was loaded onto a 20% polyacrylamide
non-denaturing gel and electrophoresed for 16 h at
100V, and then visualized by ultraviolet light after stain-
ing with ethidium bromide.
The statistical analysis of the data was carried out using
SPSS 11. In addition to descriptive statistics and chi-
square analyses, we carried out ANCOVAs and regres-
sion analyses with appropriate post hoc corrections.
Results
We considered three groups of subjects whose profiles
and findings are detailed below:
Group 1 – Patients with AD
General features of the AD group. This group comprised
337 patients, 241 women (71.5%) and 96 men (28.5%).
They presented mild to moderate severity of dementia
(CDR 1-2, MMS ≥14). Their mean years of schooling
were 5.6±2.3 (range 3-17) and their mean age was
76.5±7.8 years (range 51-92). All the patients had satis-
factory nutritional status. At the time of first examination,
39% presented one concomitant disease while 12.5%
had more than one, most commonly arterial hyperten-
sion, cardiopathies and diabetes mellitus. Drugs acting
on the CNS were used by 52.5%; 12.2% used anti-
cholinesterase inhibitors (namely, donepezil 67%, ri-
vastigmine 29%, galantamine 4%).
Features of the AD-TBI group. Twenty-one of the 337 AD
patients had a history of moderate to very severe TBI:
post-traumatic coma lasting less than an hour in four, less
than 24 hours in six, and more than 24 hours in 11. The
interval between the TBI and the examination was less
than five years in four cases, between five and 10 years
in seven cases and over 10 years in 10 cases. They had
a younger mean age (71.8 years) than the AD group as a
whole, and a higher proportion of males (11/21).
Forty-two cases were selected from the original 337 pa-
tients to serve as controls (AD-C) on the basis of com-
parable social and demographic features, age, school-
ing and severity of dementia. In 20% of both groups,
there was a family history of dementia. As seen in Table
I, which details the main socio-demographic and func-
tional variables in the two groups, the TBI group showed
more severe affective and behavioural disorders (they
had significantly higher GDS and NPI scores) and in-
creased use of antidepressive and anxiolytic medica-
tions (38% vs 19% in the AD-C group). 
Both groups were seen three times: at baseline and af-
ter 6 and 12 months (Table II). Only one patient from
each group was lost to follow up. As expected, both
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groups showed a cognitive and functional decline over
the follow up. An ANCOVA performed on the data pre-
sented in Table II with TBI as a variable failed to show
any significant difference between the two groups.
Group 2 – Patients with MCI
General features of the MCI group. This group com-
prised 63 patients, 39 women (62%) and 24 men (38%).
Their mean age was 71.5±8 years (range 51-86). The
onset of cognitive disorders had occurred, on average,
12.3±5.3 months prior to the baseline examination
(range 6-24 months). The cognitive disorder mainly in-
volved episodic memory.
Features of the MCI-TBI group. Nine of the 63 patients
with MCI presented a history of head injury, generally
more severe than that found in the AD-TBI group. In-
deed, only one subject had experienced a trauma of
moderate severity (post-traumatic loss of conscious-
ness lasting less than an hour). In three cases, the TBI
was moderate to severe, and in five cases it was severe.
The interval between the TBI and the examination was
less than five years in two cases, between five and 10
years in two cases, and over 10 years in five cases.
Eighteen of the original 63 patients were selected to
serve as controls on the basis of comparable social and
demographic features, age, and schooling. Co-morbid
events were present with the same frequency and distri-
bution in the two groups.
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Table II - Neuropsychological characteristics at baseline and at 6- and 12-month follow up of patients with Alzheimer’s dis-
ease with and without a history of traumatic brain injury.
AD-TBI AD-C
Baseline 6 Months 12 Months Baseline 6 Months 12 Months
GDS 12.3±5 11.3±.6 12.3±6 9.6±4.3 9.9±5.1 10.3±4.5
NPI 25.5±9 27.5±10 28.3±13 19.9±9 21.3±12 24.4±14
IADL 4.6±2.5 4.3±2.3 3.7±2 5.1±1.7 4.5±1.6 3.9±1.7
ADL 5.2±1.2 4.8±1.3 4.5±1.2 5.4±0.9 5.2±1.1 4.7±1.1
MMSE 19.9±3.6 18.5±36 17.3±3.8 20.5±3.4 19.2±3.3 18.3±3.9
AM 32±9 28±12 22.8±14 36±8 33±11 24±10
DS 3.5±0.5 3.3±0.6 3.0±0.6 3.7±0.6 3.3±0.5 3.1±0.7
Corsi 3.5±0.7 3.2±0.5 3.1±0.6 3.8±0.7 3.7±0.7 3.4±0.8
MDB
Verbal tests
RI 18.9±6.5 16.6±6.7 14.4±7.1 19.9±6.1 18.7±7.4 16.5±7
RD 1.4±1.8 1.4±1.7 1.1±1.9 1.6±1.6 1.5±1.4 1.3±1.5
FAS 13.8±5 12.4±7.7 9.2±7.1 14.7±5.6 13.9±7 11.4±7
SC 13±6.5 11.4±6 6.8±6.3 13.9±6.6 12.4±6.2 8.8±7
Visuospatial tests
CD f 8.6±2.3 8.0±2.3 6.9±2.8 8.9±2.7 8.5±3.1 7.5±3
CD l 46±14 42±15 38±16 49±14 47±17 41±15
IVM 13±2.8 12±3.1 10±3 15±4.8 13.2±6 11.5±5
PM 16.2±4.5 14.4±8 11.1±7.7 16.5±5.5 13.1±7.8 12.3±6.7
Abbreviations: AD-TBI=Alzheimer’s disease patients with history of traumatic brain injury; AD-C=control group of Alzheimer’s disease patients
without history of traumatic brain injury; GDS=Global Deterioration Scale; NPI=Neuropsychiatric Inventory; IADL=Instrumental Activities of Dai-
ly Living scale; ADL=Activities of Daily Living scale; MMSE=Mini Mental Status Examination; AM=Attention Matrices; DS=Digit Span; Corsi=non
verbal span; MDB=Mental Deterioration Battery; RI=Rey’s 15 word list, immediate recall; RD=Rey’s 15 word list, delayed recall; FAS=word flu-
ency (letters); SC=sentence construction; CD f=copy of drawings, freehand; CD l=copy of drawings, with landmarks; IVM=immediate visual
memory; PM=Raven’s progressive matrices.
Table I - Socio-demographic and functional data of Alzheimer’s
disease patients with and without a history of traumatic brain
injury.
AD-TBI AD-C
(n=21) (n=42)
Age 71.8±7.3 72.1±7.1
Gender (M/F) 11/10 22/20
Education in yrs 15.6±2.1 15.6±2.1
Dementia features
MMSE 19.8±3.6 20.4±3.4
GDS 12.5±5.1 9.5±4.4*
NPI 25.4±9.1 19.7±8.9*
Disease duration in months 32±20 38±16
Functional status
IADL 4.7±2.5 5.1±1.8
ADL 5.1±1.3 5.5±0.9
Comorbidity
Hypertension 7 15
Diabetes 1 13
Ischaemic cardiopathy 3 16
Tumours 2 14
* p<0.05 TBI patients vs controls.
Abbreviations: AD-TBI=Alzheimer’s disease patients with history of
traumatic brain injury; AD-C=control group of Alzheimer’s disease
patients without history of traumatic brain injury; MMSE=Mini Mental
State Examination; GDS=Global Deterioration Scale; NPI=Neu-
ropsychiatric Inventory; IADL=Instrumental Activities of Daily Living
scale; ADL=Activities of Daily Living Scale.
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Table III - Neuropsychological test results at baseline, and at 6- and 12-month follow up of patients with mild cognitive impair-
ment with and without a history of traumatic brain injury.
Tests MCI-TBI (n=9) MCI-C (n=18)
Baseline 6 Months 12 Months Baseline 6 Months 12 Months
MMSE 24.9±2.3 23.8±2.7 22.9±3.6 25.8±2.6 24.5±3.2 23.8±3.4
AM 42.1±8.9 41.6±7.7 42.6±8.7 44.0±8.4 44.5±7.4 43.9±7.4
DS 3.9±0.6 3.9±0.7 3.9±0.7 4.0±0.7 4.1±0.7 4.0±0.7
Corsi 4.2±0.4 4.0±0.6 4.0±0.7 4.5±0.9 4.4±0.8 4.4±0.9
RI 25.8± 7.5 23.9±7.8 23.6±8.8 26.5±8.3 25.3±7.5 24.7±7.8
RD 3.1±2.3 2.7±2.5 2.4±2.3 2.8±2.5 2.5±2.1 2.2±2.2
FAS 23.5±9.5 23.0±10.0 21.0±9.8 24.0±9.6 23.4±9.1 22.9±10.0
SC 17.5± 6.8 17.8±7.5 17.7±7.9 18.2±5.9 18.1±6.1 18.3±6.0
CD f 9.9±1.7 9.5±2.3 9.2±2.0 9.6±1.8 9.5±2.0 9.3±2.2
CD l 66.9±3.2 67.9±3.4 66.4±1.6 65.7±4.3 65.8±3.9 65.3±4.5
IVM 17.6±3.2 17.8±3.0 18.0±4.0 17.5±3.8 17.6±3.7 17.4±3.6
PM 23.5±4.7 22.8±4.8 21.8±5.0 24.6±4.9 24.3±5.5 23.4±5.1
Abbreviations: MCI-TBI=patients with mild cognitive impairment and a history of traumatic brain injury; MCI-C=control group of patients with
mild cognitive impairment and no history of traumatic brain injury; MMSE=Mini Mental State Examination; AM=Attention Matrices; DS=Digit
Span; Corsi=non verbal span; RI=Rey’s 15 word list, immediate recall; RD=Rey’s 15 word list, delayed recall; FAS=word fluency (letters);
SC=sentence construction; CD f=copy of drawings, freehand; CD l=copy of drawings, with landmarks; IVM=immediate visual memory;
PM=Raven’s progressive matrices.
Table IV - Neuropsychological test results in incidental cases of traumatic brain injury (I-TBI) and controls without TBI (I-C) at
baseline, 6 months and 12 months follow-up.
Tests Baseline 6 Months 12 Months Baseline 6 Months 12 Months
TBI (n=16) I-C (n=12)
MMSE 25.6±2.1 26.9±1.7 26.8±1.8 27.9±1.5 28.0±1.3 27.8±1.5
AM 39.1±6.6 40.5±6 42.0±7.0 47.5±4.2 47.8±5 49±74.6
DS 3.8±0.7 3.9±0.6 3.9±0.6 4.2±0.7 4.1±0.7 4.2±0.6
Corsi 4.3±0.5 4.4±0.6 4.5±0.6 4.6±0.5 4.7±0.5 4.7±0.5
RI 32±7.2 34.9±6.5 35.8±7.1 39.6±8 38.8±8 40±7
RD 5.6±2.0 6.1±1.7 6.2±1.8 7.7±2.4 7.9±2.3 7.5±2.6
FAS 24.8±7.5 26.6±6.3 26.9±7.4 30.4±7 31.4±6.7 30.7±5.7
SC 16.9±6.4 17±76.2 17.1±6.1 19.7±3.1 19.9±3 20±3.2
CD f 10.1±2.1 9.9±21.4 10.2±1.3 9.8±0.9 10±1.2 9.9±1
CD l 66.5±3.0 67.0±3.3 67.1±3.1 67.6±1.7 67.7±1.8 67.9±1.7
IVM 17.3±1.5 17.5±1.9 17.6±1.6 18.2±1.6 18.3±1.7 18.4±1.5
PM 24.2±5.2 25.4±4.7 25.7±4.8 28.5±3.6 28.3±4 28.6±3.7
Abbreviations: I-TBI=incidental cases of traumatic brain injury; I-C=controls without traumatic brain injury; MMSE=Mini Mental State Examina-
tion; AM=Attention Matrices; DS=Digit Span; Corsi=non verbal span; RI=Rey’s 15 word list, immediate recall; RD=Rey’s 15 word list, delayed
recall; FAS=word fluency (letters); SC=sentence construction; CD f=copy of drawings, freehand; CD l=copy of drawings, with landmarks;
IVM=immediate visual memory; PM=Raven’s progressive matrices.
Table V - Apo-E allele frequencies.
Total AD-TBI MCI-TBI Trauma Study Nationwide
n=58 n=21 n=9 n=16 controls controls
n=25
E2 16% 11.0 10 19.5% 16.5% 17.3%
E3 75% 59.5% 89% 84.5% 79.5% 87.2%
E4 19% 40.5% 11% 11.6% 11.4% 15.5%
Abbreviations: AD-TBI=Alzheimer’s disease patients with history of traumatic brain injury; MCI-TBI=patients with mild cognitive impairment and
a history of traumatic brain injury.
As seen in Table III the TBI patients showed, at baseline,
a trend towards a worse cognitive performance com-
pared with the controls, which, however, never reached
statistical significance. At 12 months, the MCI-TBI group
showed increased impairment in terms of MMS (p<.05),
long-term episodic memory (delayed Rey p<.05) and vi-
suospatial abilities (free drawing copy p<.05). However,
ANCOVA failed to show an effect of the “trauma” vari-
able.
A follow-up analysis of the clinical data and of the cogni-
tive profile of the 27 cases showed that 24 cases still
showed MCI after 12 months, whereas the picture of
three patients, one with TBI and two without, had con-
verted to one of dementia.
Group 3 – Incidental cases of recent TBI and their 
controls
This group included 16 subjects over 60 years of age
without a history of cognitive or behavioural changes pri-
or to a recent TBI. Three had suffered a mild trauma, 11
a moderate and two a moderate-to-severe TBI. A group
of 12 subjects matched for age, gender and schooling,
but without TBI, cognitive or behavioural changes, was
used as controls.
Table IV shows the cognitive performances of the two
subgroups. The patients with TBI showed a cognitive
disorder in executive functions (Raven’s PM p<0.05)
and episodic memory (Rey immediate and delayed re-
call <.05), which tended to improve during the follow-up
period.
Analysis of the Apo E genotype
The analysis was carried out in all patients with TBI (21
AD, 9 MCI) as well in the 16 incidental cases and their
12 controls. The results from these 58 subjects were
compared to the distribution within the population of AD
patients of the same age as defined by the IMSEB Cen-
tre, National Research Council, Cosenza, Italy (27).
Table V shows that 19% of the total 58 cases had an E 4
allele; this rose to 31.7% when considering the patients
with cognitive deterioration (either AD or MCI) and TBI.
In the AD-TBI group, it reached 40.5%. This compares
to 4% in a control group drawn from our own patients
made up of 25 subjects without TBI, and to 5.5% in the
overall AD population.
An analysis of the geographical distribution showed no
difference between northern Italian and southern Italian
subjects.
Discussion
We found that 6.5% of an unselected group of patients
with AD had a significant TBI. This result has to be
compared to the 8.3% recorded in the MIRAGE study
and the 11.5% found in the study by Mayeux et al. (11).
The discrepancy between our finding and those of the
other two studies could be explained by the different
methods used to record head trauma. Our method was
quite conservative. A higher frequency can be expect-
ed to emerge in studies considering a single informant,
whereas those, like ours, that consider the reports of
multiple informants and the content of medical records
are likely to find a lower percentage. As stated by Guo
et al. (12), a high level of association between head in-
jury and AD may be in part “simply an effect of recall
bias” with relatives over-reporting head injury in pa-
tients with dementia. Despite its relatively small size,
our MCI group showed a considerably higher percent-
age of TBI (14.3%). This is partially explained by the
fact that the MCI group included a higher percentage
of males.
The distribution of Apo E 4 showed a very marked in-
crease in AD-TBI compared to the AD-C patients. An in-
crease was also found in the MCI-TBI patients com-
pared to those without trauma. These results strongly
suggest a synergistic interaction of environmental and
genetic factors in the development of dementia, due to
the higher frequency of TBI and Apo E 4 genotype
among AD patients. 
Our finding of a synergistic interaction is in agreement
with several previous studies (10,28-31). Also, Friedman
et al. (32) demonstrated a strong association between
Apo E 4 and a poor clinical outcome following TBI, im-
plying genetic susceptibility to the effect of brain injury.
The results reported by Plassman et al. (33) are along
the same lines, even though a trend towards a stronger
association between AD and head injury in patients with
more Apo E 4 alleles was found only in men and was not
significant. On the other hand, Chamelian et al. (34) did
not find an association between Apo E 4 and TBI out-
come. Two studies give more complex results. Guo et al.
(12) found that the influence of head injury on the risk of
AD appears to be greater among persons lacking Apo E
compared with those having one or two Apo E 4 alleles.
Another autopsy-based study (35) gave similar results.
These two studies would indicate an additive rather than
a synergistic relation between TBI and Apo E 4.
Some studies do not support an association of TBI with
AD (6-9). However, our findings as well as those of oth-
er studies reporting an association are compatible with
the results of several animal studies. For instance,
Sabo et al. (14) showed that transgenic mice express-
ing human Apo E 4 have a worse outcome following
closed head injuries. Another study has shown that
repetitive TBI accelerates brain Abeta accumulation
and oxidative stress as well as cognitive impairment in
a transgenic mouse model of Alzheimer amyloidosis
(15).
The neuropsychological profile of AD patients with TBI
did not differ from that of AD patients without TBI. This
was also true of the MCI patients. Furthermore, a previ-
ous brain trauma was not found to contribute to a more
rapid conversion to dementia. Although the follow-up pe-
riod in this study was not very long, our data thus far
suggest that the presence of Apo E 4 and a history of
TBI contribute to the appearance of AD, but do not influ-
ence its clinical presentation or course.
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